Intrinsiqs

Is UroGen Pharma Ltd. overvalued?

UroGen Pharma Ltd. (URGN) — key valuation metrics and fundamentals.

No verdict
Price
$26.18
Fair value
—
Current P/E
—
Normal P/E
—
Market cap
$1.28B
Dividend yield
0.0%
Return on equity
54.0%
Sector
Healthcare

See the full interactive analysis →

Fair value compares URGN's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 12 Nov 2026.